阻碍成功减肥的分子机制和对肥胖的有希望的治疗方案
Zsolt Szekeres1, Eszter Szabados2, Anita Pálfi2
1Department of Laboratory Medicine, Medical School, University of Pecs, H-7624 Pecs, Hungary.
Biomedicines
|August 28, 2025
概括
肥胖症涉及复杂的分子机制,如代谢记忆和表观遗传, 新型疗法有前途, 但长期有效性需要进一步研究,
科学领域:
- 肥胖的分子机制
- 代谢性疾病
- 内分泌学
背景情况:
- 肥胖是一个复杂的健康问题,其原因包括生活方式,遗传和神经内分泌因素.
- 尽管有干预措施, 持续减肥仍然是一个重大挑战.
- 了解分子机制对于开发有效的肥胖治疗至关重要.
研究的目的:
- 审查目前关于阻碍减肥的分子机制的知识.
- 总结肥胖管理的新兴治疗策略.
- 提供关于肥胖治疗复杂性的见解.
主要方法:
- 对PubMed,Scopus和Web of Science数据库的综合文献审查.
- 包括同行评审的原始文章,系统评论和元分析.
- 专注于过去十年 (2015-2025年) 中发表的研究,并考虑具有历史意义的作品.
主要成果:
- 肥胖是一种慢性疾病, 需要个性化, 多学科的方法.
- 关键的分子机制包括代谢记忆,表观遗传学 (DNA / 基因组修饰,microRNAs) 和脂肪组织功能障碍.
- 脂肪组织功能障碍导致炎症和胰岛素抵抗,加剧肥胖.
- 脂肪细胞类型 (白色,色,棕色) 的平衡影响能量调节.
- 新的医疗干预措施有潜力抵消减肥障碍.
结论:
- 综合干预措施 (饮食,运动,药物治疗) 具有治疗肥胖的潜力.
- 目前和新型干预措施的长期疗效和安全性需要进一步研究.
- 个性化和多学科策略对于有效的肥胖管理至关重要.
相关概念视频
Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
Regulation of Food Intake
350
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
350
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K


